Bernstein upgraded Humana to Outperform from Market Perform with a $308 price target. Medicare Advantage star risks are being incorporated into expectations and the share price, while the sector outlook is improving and the stock has potential upside catalysts, the analyst tells investors in a research note. The firm believes Humana is now an attractive investment given the improved operating outlook for Medicare Advantage, reduced uncertainty on risks such as starts ratings and repricing execution as some become realized, the reduced stock price, and an “improved balance of upside risks vs downside risks.”